Stock AnalizTwist Bioscience Corp TWST
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Twist Bioscience Corp (TWST) is a healthcare company listed in the US with a market value of about $7.4B. In the twelve months to September 30, 2026 it had revenue of $459M and net income of -$130M, a net margin of -28.3%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 33% a year, a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $459M | $377M | $313M | $245M | $204M | $132M | $90M | $54M | $25M | $11M |
| Net income | -$130M | -$78M | -$209M | -$205M | -$218M | -$152M | -$140M | -$108M | -$71M | -$59M |
| Free cash flow | — | -$76M | -$69M | -$170M | -$226M | -$139M | -$152M | -$103M | -$70M | -$58M |
| EPS (diluted) | $-2.08 | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 | $-3.92 | $-0.03 | $-24489.86 |
| Net margin | -28.3% | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | -155.3% | -198.0% | -280.2% | -550.9% |
| ROIC | — | -19.6% | -31.3% | -23.9% | -25.3% | -23.4% | -29.7% | -53.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $134.75, 21% above the current price; targets range from $45.00 to $190.00; the consensus rating is “Buy”; expected EPS is $-0.52 for the fiscal year ending September 30, 2027.
Frequently asked questions
Is Twist Bioscience stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Twist Bioscience pay a dividend?
Not currently.
Is Twist Bioscience a good stock to buy?
We do not give buy or sell advice. Twist Bioscience scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.